Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 13/20 | 0.48 |
| ▸ | CXCR2 | P25025 | 9/20 | 0.48 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.48 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.48 |
| ▸ | CCR4 | P51679 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1705871 | 0.93 | CXCR2 (0.52) | CCR6CXCR2CXCR1CXCR3CCR4 | |
| SCHEMBL1706018 | 0.92 | CCR6 (0.57) | CCR6CXCR2CXCR1CXCR3CCR4 | |
| SCHEMBL3352829 | 0.92 | CCR6 (0.57) | CCR6CXCR2CXCR1CXCR3CCR4 | |
| SCHEMBL1706285 | 0.91 | CCR6 (0.47) | CCR6CXCR2CXCR1CXCR3CCR4 | |
| SCHEMBL1705851 | 0.90 | CCR6 (0.48) | CCR6CXCR2CXCR1CXCR3CCR4 | |
| SCHEMBL1705868 | 0.90 | CXCR2 (0.53) | CCR6CXCR2CXCR1CXCR3CCR4 | |
| SCHEMBL1705859 | 0.90 | CCR6 (0.48) | CCR6CXCR2CXCR1CXCR3CCR4 | |
| SCHEMBL14008427 | 0.90 | CCR6 (0.48) | CCR6CXCR2CXCR1CXCR3CCR4 | |
| SCHEMBL14008425 | 0.90 | CCR6 (0.49) | CCR6CXCR2CXCR1CXCR3CCR4 | |
| SCHEMBL1705908 | 0.90 | CCR6 (0.49) | CCR6CXCR2CXCR1CXCR3CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183281-B2 | CXC-chemokine receptor ligands | NOVARTIS AG (CH) | 2012-05-22 | — | — | US | claimed |
| EP-2155670-B1 | ANTI -INFLAMMATORY SUBSTITUTED CYCLOBUTENEDIONE COMPOUNDS | NOVARTIS AG (CH) | 2012-04-18 | — | — | EP | claimed |
| US-8183281-B2 | CXC-chemokine receptor ligands | NOVARTIS AG (CH) | 2012-05-22 | — | — | US | disclosed |
| US-8183281-B2 | CXC-chemokine receptor ligands | NOVARTIS AG (CH) | 2012-05-22 | — | — | US | disclosed |
| US-8183281-B2 | CXC-chemokine receptor ligands | NOVARTIS AG (CH) | 2012-05-22 | — | — | US | disclosed |
| EP-2155670-B1 | ANTI -INFLAMMATORY SUBSTITUTED CYCLOBUTENEDIONE COMPOUNDS | NOVARTIS AG (CH) | 2012-04-18 | — | — | EP | disclosed |
| US-20100125071-A1 | CXC-CHEMOKINE RECEPTOR LIGANDS | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
| US-20100125071-A1 | CXC-CHEMOKINE RECEPTOR LIGANDS | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
| US-20100125071-A1 | CXC-CHEMOKINE RECEPTOR LIGANDS | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
| WO-2008148790-A1 | ANTI -INFLAMMATORY SUBSTITUTED CYCLOBUTENEDIONE COMPOUNDS | NOVARTIS AG (CH) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125071-A1 | CXC-CHEMOKINE RECEPTOR LIGANDS | CXCR2, CXCR1, CX3CR1 | CCR6 20/4885CXCR2 1/4885CXCR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.